Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Launched by CHINESE PLA GENERAL HOSPITAL · Jan 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the balance of bacteria in the gut (the microbiome) and the body’s immune system interact in patients who have a specific type of skin and muscle disease called dermatomyositis, particularly those who also have a related condition known as rapidly progressive interstitial lung disease (RPILD). The researchers want to understand how these factors might affect each other in people who test positive for a certain antibody (anti-MDA5).

To participate in this study, individuals must be at least 18 years old and diagnosed with dermatomyositis linked to the anti-MDA5 antibody. They should also have undergone a specific lung procedure called bronchoalveolar lavage. However, people with other autoimmune diseases, certain infections, or who are pregnant or breastfeeding cannot join. Those who participate can expect to contribute to important research that could help improve understanding and treatment of these conditions. The trial is currently recruiting participants, and all involved will sign consent forms to ensure they understand what the study entails.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
• • Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
• • Must have undergone bronchoalveolar lavage.
• • Age≥18 years old.
• • Patients who signed informed consent forms
• Exclusion Criteria:
• • Patients who had other connective tissue diseases.
• • Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
• • Pregnant or lactating patients.
• • The patient also participated in any other clinical trial.
• • Disagreement for inclusion in this study